ocuphire is a new biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. ocuphire’s lead drug candidate, nyxol eye drops, is aimed to treat patients with night vision disturbances (nvd), glaucoma and presbyopia (impaired near-term vision). ocuphire is in discussions with a prospective late stage ophthalmic drug program that could be developed in parallel. ocuphire's management team has over 100 years of drug development expertise across a diverse set of therapeutic areas including ophthalmology, orphan, cardio-metabolic, nephrology, oncology and respiratory.
Company profile
Ticker
OCUP
Exchange
Website
CEO
Douglas Swirsky
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK, REXAHN PHARMACEUTICALS, INC.
SEC CIK
Corporate docs
Subsidiaries
OcuSub, Inc. ...
IRS number
113516358
OCUP stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Regulation FD Disclosure
10 May 24
8-K
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
10 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
8-K
Departure of Directors or Certain Officers
17 Apr 24
8-K
Regulation FD Disclosure
27 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.16 mm | 47.16 mm | 47.16 mm | 47.16 mm | 47.16 mm | 47.16 mm |
Cash burn (monthly) | 1.11 mm | (no burn) | 2.57 mm | 1.01 mm | 1.91 mm | 265.17 k |
Cash used (since last report) | 1.94 mm | n/a | 4.48 mm | 1.76 mm | 3.32 mm | 462.46 k |
Cash remaining | 45.22 mm | n/a | 42.68 mm | 45.40 mm | 43.84 mm | 46.70 mm |
Runway (months of cash) | 40.6 | n/a | 16.6 | 44.9 | 23.0 | 176.1 |
Institutional ownership, Q4 2023
3.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 47 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 97.88 mm |
Total shares | 810.96 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Apexian Pharmaceuticals | 779.99 k | $4.68 mm |
Trust Co Of Toledo Na | 30.96 k | $93.20 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 May 24 | George Magrath | Common Stock | Buy | Acquire P | No | No | 1.7545 | 5,000 | 8.77 k | 430,000 |
11 Apr 24 | Jay Pepose | Common Stock | Grant | Acquire A | No | No | 0 | 32,000 | 0.00 | 139,315 |
11 Apr 24 | Jay Pepose | Stock Option Common Stock | Grant | Acquire A | No | No | 1.79 | 48,000 | 85.92 k | 48,000 |
21 Mar 24 | Joseph K Schachle | Common Stock | Buy | Acquire P | No | No | 2.05 | 2,000 | 4.10 k | 2,000 |
21 Mar 24 | Nirav S. Jhaveri | Common Stock | Buy | Acquire P | No | No | 2.1 | 10,000 | 21.00 k | 150,000 |
18 Mar 24 | George Magrath | Common Stock | Buy | Acquire P | No | No | 1.962 | 25,000 | 49.05 k | 425,000 |
News
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
22 May 24
Canaccord Genuity Maintains Buy on Ocuphire Pharma, Lowers Price Target to $18
13 May 24
HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
13 May 24
Ocuphire Pharma Q1 2024 GAAP EPS $(0.29) Misses $(0.13) Estimate
10 May 24
12 Health Care Stocks Moving In Thursday's After-Market Session
11 Apr 24
Press releases
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
10 May 24
Ocuphire Pharma to Present at the Aegis Virtual Conference
3 May 24
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
11 Apr 24
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
23 Feb 24